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AbstrAct
background A patient decision aid (PDA) is a tool 
for shared decision making (SDM), which emphasises 
patient empowerment. It is useful in chronic diseases 
and when there are multiple, no best single treatment 
option. Although SDM is prevalent in Western countries, 
its use is limited in Chinese societies, where the adoption 
of a paternalistic approach is strong. Here, we report the 
development, acceptance and pilot test results of a PDA 
targeted at Chinese patients with primary open-angle 
glaucoma (POAG).
Methods We developed a PDA designed for use in 
Chinese patients with POAG. Recruited subjects were given 
our PDA. Baseline evaluation included decision conflict 
scale (DCS), validated glaucoma adherence questionnaires 
and glaucoma knowledge questionnaire. Subjects were 
briefed through the PDA and instructed to read it that 
day. Three to four weeks later, follow-up questionnaire 
as described above were conducted with the addition of 
acceptance questionnaires.
results Data from 65 subjects were available. The PDA 
was well received among subjects. DCS improved from 
48.9±20.4 at baseline to 34.3±20.3 during follow-up, with 
P<0.01. Validated medication adherence questionnaires 
and knowledge showed improvement from baseline, which 
was statistically significant.
conclusions The use of PDA among Chinese 
subjects with POAG demonstrated positive reception 
and acceptance. Evaluation of its initial effects shows 
improvement in DCS, medication adherence and glaucoma 
knowledge. The implementation of SDM and PDA among 
Chinese subjects with POAG is encouraged. Future studies 
with randomised design and later evaluation time points 
can further reveal the impacts of PDA among Chinese 
subjects with POAG.
IntroductIon
Paternalistic healthcare delivery, which 
features dominant doctors and passive 
patients, is becoming obsolete. Shared deci-
sion making (SDM) emphasises patient 
autonomy, informed consent and patient 
empowerment.1 Studies have shown that 
patients usually make decisions based on 
emotions such as trust rather than medical 
information. A patient decision aid (PDA) 
is a tool to promote SDM and solve deci-
sion conflict. PDAs can be used when there 
are multiple treatment options available and 
where each option has benefits and harms 
that different patients may value differently.2 
The International Patient Decision Aid 
Standards (IPDAS) Collaboration has devel-
oped criteria to judge the quality of PDAs 
(online supplementary appendix 1).3–5 This 
includes a systematic development, provision 
of evidence-based information about treat-
ment options and probabilities, clarification 
of patients’ values, balanced presentation of 
options and using plain language. A Cochrane 
systematic review of more than 80 studies 
shows that PDAs have numerous benefits: 
greater knowledge, more accurate risk and 
benefit perceptions, greater comfort with 
decisions and greater participation in deci-
sion making among patients. There is also 
some evidence that the use of PDA leads to 
more conservative decisions with reduced 
choice of surgery.2
The use of PDAs is widely adapted in 
chronic diseases,6–9 where outcomes for 
various treatment options may be less certain, 
offering a wider scope for patient autonomy. 
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Key messages
What is already known about this subject?
Application of shared decision making (SDM) and 
patient decision aid (PDA) in Western countries has 
been shown to have multiple benefits for patients, 
for example, greater knowledge, more accurate risk 
perception and less decision conflict.
What are the new findings?
Pilot testing of PDA among Chinese patients with 
primary open-angle glaucoma shows good acceptance, 
with improved knowledge, medication adherence and 
decision conflict.
How might these results change the focus of 
research or clinical practice?
There is a potential role for implementing SDM and 
PDA into regular practice in Asia.
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In contrast, acute decisions are often urgent and may 
involve the clinician in a more paternalistic role.
Glaucoma is the leading cause of global irreversible 
but preventable blindness.10 An estimate of 9 million 
of global blindness is attributed to glaucoma. The total 
number of patients with glaucoma is estimated to increase 
to 79.6 million by 2020. Population studies found that 
glaucoma disproportionately affects Asians, with Asians 
accounting for 47% of those with glaucoma.11 The esti-
mates in 2013 for the number of people with primary 
open-angle glaucoma (POAG) in Asia were 33.45 million. 
This is estimated to increase by 16% in 2020.12 China, with 
its population of 1.3 billion, has an estimated prevalence 
of approximately 1% of the population suffering from 
POAG. This number is expected to rise with increasing 
life expectancy.
In Hong Kong, although glaucoma is the leading cause 
of blindness, the general public’s knowledge of glaucoma 
is limited. In a study conducted to investigate the level 
of knowledge of eye diseases in the Hong Kong Chinese 
population, only 10.2% could describe glaucoma symp-
toms correctly, 1.1% described either the anatomy or 
physiology correctly and 9.6% were able to mention either 
surgery, laser or drugs as a form of treatment.13 Treatment 
choice for glaucoma involves many options and is complex, 
each with its own pros and cons. Due to the chronic nature 
of glaucoma, these treatment choices require a level of 
commitment, be it in the form of compliance or frequent 
follow-up. We therefore hypothesise that patients with glau-
coma would benefit from the introduction of SDM and 
PDAs.
Regarding the use of PDAs in ophthalmology, the 
National Health Service has developed a PDA for 
patients with cataract (online supplementary appendix 
2). An open-angle glaucoma PDA has been developed 
by the Johns Hopkins University Evidence-based Practice 
Center (online supplementary appendix 3). Although 
SDM is prevalent in Western countries, its use is limited 
in Chinese societies, where the adoption of a paternal-
istic approach is strong. This may be due to inherent 
differences in Chinese culture and values. To the best of 
our knowledge, there have been no ophthalmology PDAs 
designed for the Asian population to date.
Here, we report the development, acceptance and pilot 
test results of a PDA targeted at Chinese patients with 
POAG.
MetHod
development of draft PdA booklet and criteria IPdAs 
fulfilment
To develop a high-quality PDA, we respected the IPDAS 
criteria, which mainly addresses clinical content, develop-
ment process and evaluation of a PDA’s effectiveness3 5 (see 
online supplementary appendix 1). In terms of content, 
information was provided on nature of the disease, different 
treatment options with their pros and cons and clarification 
of patients’ own values. In terms of development process, 
plain language was used. Six ophthalmology specialists with 
glaucoma subspecialty training from different hospitals 
were involved in the drafting of content, with peer review 
conducted by two senior glaucoma specialists. In terms 
of effectiveness evaluation, field testing of the PDA was 
kindly offered by patients from the Hong Kong Glaucoma 
Patients Association. This led to the addition of common 
patient concerns regarding different treatment options 
and a treatment option comparison overview to our PDA. 
The final booklet consisted of five chapters: background 
information on POAG (anatomy and disease course); pros, 
cons and common patient concerns regarding glaucoma 
eyedrops, trabeculoplasty and trabeculectomy, respectively; 
and a table overview and comparison of different treatment 
options. There is also a final section consisting of question-
naires for patient acceptance threshold towards different 
treatment options (online supplementary appendix 4).
Apart from respecting the IPDAS criteria, local values 
and preferences have also been taken into consideration 
in the development process. A local expertise on patient 
education had developed a PDA targeted at Chinese 
patients with breast cancer.4 14 15 A local survey showed 
preference of booklet presentation method to audio-
tape–booklet combination and interactive computer 
programs. Diagrams were preferred to texts, and the 
preferred method of numerical and comparison presen-
tations were also adopted.4
Participants, setting and measures
Recruitment took place at the Hong Kong West Cluster 
Ophthalmology outpatient clinic, from February to June 
2016. Inclusion criteria were adult patients aged 18 years 
or above, patients with POAG and Chinese literacy. 
Exclusion criteria were illiterate subjects, subjects who 
have difficulty understanding our PDA booklet, angle 
closure glaucoma with any quadrant of angle closure on 
gonioscopy, history of iridotomy, secondary glaucoma 
and non-Chinese subjects.
Participating subjects were given a copy of our Chinese 
POAG PDA. The contents were briefly covered in a 5 min 
briefing conducted by our research assistant. They then 
underwent a baseline evaluation, which included demo-
graphic information and questionnaires addressing the 
following areas: medication adherence, decision conflict, 
glaucoma knowledge and current patient satisfaction with 
their current treatment and decision. The questionnaires 
included the following: a validated 10-item glaucoma 
medication adherence self-efficacy scale (10-GMASS)),16 
the Morisky 8-item medication adherence questionnaire 
(8-MMAQ),17 18 the traditional 16-item five-response 
decision conflict scale (DCS),19 a questionnaire to eval-
uate the patient’s general glaucoma knowledge and a 
questionnaire evaluating patient satisfaction with their 
treatment and decision making adapted from a previous 
study.4 The 10-GMASS and 8-MMAQ were translated into 
Chinese by a bilingual researcher. The translation was 
reviewed for clarity by another bilingual researcher. For 
the DCS, an official Chinese version is available for use. 
For the glaucoma knowledge questionnaire, it consisted of 
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Table 1 Improvement from baseline in medication adherence, decision conflict and glaucoma knowledge
Questionnaire Result
Score deviation from 
baseline (mean±SD) 95% CI P value
10-GMASS Improved adherence −19.8±2.0 (−16 to 23.5) <0.01
8-MMAQ Improved adherence −0.8±0.3 (−0.2 to 1.4) =0.01
DCS Decreased conflict −14.5±2.4 (−9.7 to 19.3) <0.01
Glaucoma knowledge Improved knowledge   2.5±0.3   (1.9 to 3.1) <0.01
8-MMAQ, Morisky 8-item medication adherence questionnaire; 10-GMASS, 10-item glaucoma medication adherence self-efficacy scale; 
DCS, decision conflict scale.
12 questions that evaluated core concepts that encom-
passed glaucoma anatomy, symptoms and pros and cons of 
medications, trabeculoplasty and trabeculectomy, respec-
tively.
Subjects were then instructed to read through the 
PDA at home. A follow-up evaluation was conducted 3–4 
weeks later via telephone. All above questionnaires were 
repeated, along with evaluation of the PDA’s acceptance 
and utility. The acceptance and utility questionnaires 
were adopted from a previous study,4 which was derived 
from the Ottawa Health Decision Center questionnaire. 
It addressed the comprehensibility of components of 
the draft, its length, amount of information, balance in 
presentation of options and overall suitability for deci-
sion making.20 21
data analysis
Descriptive statistics was used to delineate the accept-
ability and utility of PDA. Primary outcome include 
comparison of all questionnaire scores before and after 
the use of PDA. Paired t-test was used for continuous 
data, and McNemar’s test was used for categorical data. 
F-test and two-sample t-test were used to evaluate whether 
baseline factors acted as confounding variables. Statistical 
analysis was carried out by the Biostatistics and Clinical 
Research Methodology Unit of the University of Hong 
Kong. Software used was R (V.3.2.3, CA1, USA).
results
A total of 78 subjects were recruited into the study. 
Four subjects declined baseline evaluation after reading 
through the PDA. Nine subjects declined follow-up eval-
uation. Thus, data from 65 subjects were available for 
analysis.
There were 36 male and 29 female participants. The 
mean age was 67.7±11.1 years. The subjects have been 
diagnosed with glaucoma for an average of 6.9±5.4 
years. Sixty-four subjects currently require eyedrops for 
disease control, while one subject is medication free 
after previous intervention. Ten subjects have previously 
received selective laser trabeculoplasty and four had 
underwent filtration surgery.
Statistically significant improvement was observed across 
10-GMASS, 8-MMAQ, DCS and glaucoma knowledge 
with findings outlined in table 1. For the 10-GMASS, each 
question used a scale from 1 to 10, with 1 indicating very 
confident and 10 indicating very unconfident. Thus, a total 
score of 10 indicates the best adherence, while 100 indicates 
the worst. The subjects scored a mean score of 28.6±14.8 
during baseline and 20.6±11.7 during follow-up, respec-
tively. For the 8-MMAQ, a score of >2, 1–2 and 0 indicated a 
low, medium and high medication adherence, respectively. 
The subjects scored a mean score of 1.9±2.1 during baseline 
and 1.0±2.3 during follow-up, respectively. For the DCS, 
the score ranges from 0 to 100, with 0 indicating no deci-
sion conflict and 100 indicating extremely high decision 
conflict. Scores lower than 25 are implementing decisions, 
while those higher than 37.5 are associated with decisional 
delay or uncertainty.19 The subjects scored a mean score of 
48.9±20.4 during baseline and 34.3±20.3 during follow-up, 
respectively. There were a total of 12 questions for the glau-
coma knowledge questionnaire. Counting the number of 
questions answered correctly, the subjects achieved a mean 
number of 6.3±2.3 correct answers during baseline and 
8.8±2.0 correct answers during follow-up, respectively.
Simple linear regression test was used to test whether 
diagnosed POAG duration was a confounder in the 
parameters listed above. No statistically significant associ-
ation was found between diagnosed POAG duration and 
medication adherence, DCS and glaucoma knowledge. 
Two sample t-test was used to test whether the patient’s 
treatment experience (eyedrops only or history of laser 
or surgery) acted as a confounder. For subjects who had 
received eyedrops only, there was a statistically significant 
improvement in 10-GMASS (P=0.003), while no such 
observation was seen with 8-MMAQ. No statistically signif-
icant association was observed with DCS and glaucoma 
knowledge.
The evaluation of patients’ satisfaction with their 
treatment and decision before and after the use of PDA 
is shown in table 2. A trend of increased satisfaction 
after the use of PDA can be observed across all ques-
tions. Generalised McNemar (Stuart-Maxwell) test was 
conducted to test the significance of this increase in satis-
faction. Significant changes were observed in questions 
1, 6, 7, 9 and 10.
The utility and acceptance of the PDA is shown in 
table 3. Although less patients read each subsequent 
chapter, 94% of subjects had completed reading the 
entire PDA. The overall acceptance of the PDA is fair. 
Sixty-two per cent of the subjects found the PDA to be of 
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Table 2 Patients treatment and decision satisfaction before and after patient decision aid (PDA) use
Before or 
after PDA
Strongly 
disagree (%)
Somewhat 
disagree (%)
Somewhat 
agree (%)
Strongly 
agree (%)
P value, 
(generalised 
McNemar test)
Among all treatment options, I 
understand the reasons I am receiving 
my current treatment.
Before 15.4 61.5 23.1   0 <0.05
After 4.6 64.6 23.1 7.7
I feel strongly dissatisfied towards the 
side effects of my current treatment.
Before 9.2 63.1 24.6 3.1 0.91
After 6.2 67.7 23.1 3.1
I feel satisfied with my current treatment. Before 12.3 61.5 26.2   0 0.27
After 9.2 63.1 21.5 6.2
I wonder if other treatment options would 
be more suitable for me.
Before 9.2 61.5 27.7 1.5 0.99
After 9.2 61.5 29.2   0
I was unable to recall the information 
given by my doctor.
Before 6.2 50.8 36.9 6.2 0.26
After 13.8 56.9 29.2   0
I had a hard time making a treatment 
decision as my doctor was unavailable to 
answer my questions.
Before 6.2 44.6 41.5 7.7 <0.05
After 24.6 46.2 26.2 3.1
I had a hard time making a treatment 
decision as I did not know how to ask 
questions.
Before 6.2    40 46.2 7.7 <0.05
After 21.5 53.8 21.5 3.1
I had a hard time making a treatment 
decision as nobody was able to help me 
make a decision.
Before 7.7 44.6 36.9 10.8 0.14
After 21.5 53.8 21.5 3.1
I had a hard time making a treatment 
decision as I did not know what 
questions to ask.
Before 7.7 44.6    40 7.7 <0.05
After 27.7 44.6 24.6 3.1
I had a hard time making a treatment 
decision as I did not know what 
treatment was best for me.
Before 6.2 49.2 32.3 12.3 <0.05
After 26.2 49.2 23.1 1.5
Table 3 The utility and acceptance of PDA
Chapter
Subjects who read 
the chapter (%)
Acceptance (%)
Good/bad
1. Anatomy and 
physiology
100 55/45
2. Medications 98 61/39
3. Selective laser 
trabeculoplasty
95 60/40
4. Penetrating surgery 95 65/35
5. Overview and 
comparison of 
treatment options
94 68/32
6. Questionnaires on 
treatment acceptance
94 59/42
PDA, patient decision aid.
optimal length and content, while 35% found it to be too 
long and 3% found it too short. Sixty-six per cent found 
the presentation of treatment options to be balanced 
with no bias towards any particular treatment, while 9% 
felt the PDA favoured medications, 11% felt the PDA 
favoured trabeculoplasty and 14% felt the PDA favoured 
surgery. Sixty per cent of subjects found the PDA enabled 
them to understand their disease better, while 29% 
were neutral and 11% disagreed. Eighty-five per cent of 
subjects found the PDA helped them feel more informed 
and comfortable about their glaucoma treatment option, 
while 15% disagreed.
dIscussIon
Our study is unique in its describing the design, applica-
tion and testing of PDA during glaucoma clinical care in 
an Asian metropolitan setting and offers insight to the 
usefulness of PDA in the Chinese cultural context.
Pilot testing of the PDA showed significant improve-
ment in terms of medication adherence, decision conflict 
and knowledge among patients with POAG. Compliance 
plays a huge role in the treatment outcome of glaucoma. 
Studies have shown that nearly half of all subjects started on 
glaucoma medications will discontinue treatment within 6 
months.22 23 The mean age of our subjects with POAG is 
nearing 70 years. For elderly patients to have good compli-
ance and dedication requires understanding of treatment 
purpose, treatment options, advantages and disadvantages 
that these options carry and the acceptance of possible 
side effects. Both the 10-GMASS and 8-MMAQ have been 
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validated and shown to accurately reflect medication adher-
ence. The 10-GMASS has been shown to be significantly 
associated with objective electronic measure of adherence. 
DCS reliably correlates with constructs of knowledge, 
regret and discontinuance, reliably differentiates between 
those who make decisions and those who delay decisions. 
Finally, improving knowledge has been shown to be posi-
tively associated with improving compliance.24
It was interesting to observe that subjects who have only 
received eyedrops as treatment demonstrated a greater 
improvement in 10-GMASS. When compared with those 
who have previously received additional intervention, 
subjects on eyedrops only may feel more compelled to 
improve their compliance. However, this effect was not 
seen with 8-MMAQ. We hypothesise that this may be due 
to the 10-GMASS having a more detailed and wider range 
for scoring when compared with 8-MMAQ.
Our study has a few limitations. The follow-up question-
naires were conducted in 3–4 weeks’ time. Glaucoma is a 
chronic disease, and this is a relatively short time frame to 
evaluate the effect of an intervention. The follow-up ques-
tionnaires were conducted by phone, and subjects would 
have the opportunity to refer to the PDA when their knowl-
edge is evaluated, which may overestimate the impact of 
the PDA. This was avoided as much as possible by our 
research assistant encouraging prompt answers and asking 
subjects to refrain from referring to the PDA. The study 
can be improved by increasing the sample size and supple-
menting ocular characteristics of recruited subjects. There 
may be a possibility of selection bias. Finally, by choosing 
a booklet form for PDA, our study does not evaluate the 
effect of SDM on illiterate subjects, which still constitutes a 
portion of our patients with POAG.
In summary, this study demonstrates that PDA is well 
received and accepted in an Asian metropolitan setting. 
The outcome also highlights the potential benefits that may 
be reaped by patients, doctors and society alike. Suggestions 
for future study directions include looking into the impact 
of PDA on patient with POAG treatment preference, its 
impact on decision regret scale that reflects satisfaction with 
the final decision,25 evaluating the impact at a later time 
frame and using a randomised controlled design.
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